BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 123418
Published online Jan 21, 2027. doi: 10.3748/wjg.123418
Table 1 Comparison of clinical features and treatment patterns between patients with mild-to-moderate and moderate-to-severe ulcerative colitis

Mild-to-moderate (n = 1674)
Moderate-to-severe (n = 208)
P value
Female726 (43.4)98 (47.1)0.341
Age at onset, years38.86 (28.19-50.38)37.26 (27.26-50.10)0.431
Age at diagnosis, years39.83 (28.80-51.96)38.29 (28.10-52.19)0.629
Time period of diagnosis
    1999-2014468 (28.0)54 (26.0)0.600
    2015-20241206 (72.0)154 (74.0)
Disease extent at diagnosis
    E1433 (25.9)1 (0.5)< 0.001
    E2336 (20.1)29 (13.9)
    E3429 (25.6)128 (61.5)
    Unknown476 (28.4)50 (24.0)
Overall therapeutic exposure
    Corticosteroids374 (22.3)206 (99.0)< 0.001
    Immunomodulators116 (6.9)53 (25.5)< 0.001
    AT469 (28.0)117 (56.2)< 0.001
Years to corticosteroids2.26 (0.88-5.52)0.00 (0.00-0.01)< 0.001
Years to immunomodulators3.07 (1.64-6.19)0.90 (0.07-3.09)< 0.001
Years to AT3.71 (1.34-7.98)0.92 (0.05-4.09)< 0.001
Highest grade of medical therapy
    5-ASA1057 (63.1)-< 0.001
    Corticosteroids101 (6.0)68 (32.7)
    Immunomodulator47 (2.8)23 (11.1)
    AT469 (28.0)117 (56.2)
Type of first-line AT1
    Anti-TNF156 (33.3)64 (54.7)< 0.001
    Vedolizumab248 (52.9)41 (35.0)
    Ustekinumab4 (0.9)0 (0.0)
    JAK inhibitors3 (0.6)4 (3.4)
    Others258 (12.4)8 (6.8)
Efficacy of first-line AT at induction
    Clinical response330 (70.4)71 (60.7)0.111
    Primary nonresponse113 (24.1)39 (33.3)
    Unknown26 (5.5)7 (6.0)
Number of AT types
    1339 (20.3)73 (35.1)< 0.001
    ≥ 2130 (7.8)44 (21.2)
    No AT1205 (72.0)91 (43.8)
Colectomy101 (6.0)52 (25.0)< 0.001


Write to the Help Desk